Eli Lilly's lymphoma drug fails in late-stage trial
May 10 (Reuters) - Eli Lilly and Co said it will stop developing its experimental cancer drug after a late-stage trial failed to show a statistically significant increase in patients' disease-free survival.
The drug, enzastaurin, was being tested in lymphoma patients who were at high risk of relapse following a chemotherapy treatment. Lymphoma is a cancer of the lymphatic system.
The decision to stop the drug's development will result in a second-quarter charge of about $30 million but the company's 2013 forecast remained unchanged, Lilly said in a statement.
- French warplanes search Mali desert for crashed Air Algerie plane |
- At least 15 killed by shelling of Gaza school; toll exceeds 760 |
- Exclusive: Ukraine rebel commander acknowledges fighters had BUK missile
- U.S. House panel votes to authorize lawsuit against Obama
- Lawyers call for outside probe of 'bungled' Arizona execution |